Zymeworks Inc. (ZYME) – What Are Brokerages Saying About This Stock?

Shares of Zymeworks Inc. (NASDAQ:ZYME – Get Free Report) have been given an average rating of “Moderate Buy” by the fourteen research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twelve have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $43.25.

A number of research firms have issued reports on ZYME. B. Riley Financial restated a “buy” rating and set a $44.00 target price (up from $40.00) on shares of Zymeworks in a research report on Monday, August 10th. Wells Fargo & Company increased their price target on Zymeworks from $37.00 to $40.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Citigroup lifted their price objective on Zymeworks from $39.00 to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, November 11th. Jefferies Financial Group reiterated a “buy” rating and issued a $52.00 price objective on shares of Zymeworks in a report on Friday, October 23rd. Finally, Wolfe Research assumed coverage on Zymeworks in a research note on Thursday, September 17th. They issued an “outperform” rating on the stock.

Get Our Latest Stock Report on Zymeworks

Zymeworks Price Performance

NASDAQ:ZYME opened at $26.24 on Monday. The company’s 50-day moving average price is $27.32 and its two-hundred day moving average price is $25.48. The firm has a market cap of $1.81 billion, a PE ratio of 50.46 and a beta of 1.32. Zymeworks has a 12 month low of $18.20 and a 12 month high of $31.97.

Zymeworks (NASDAQ:ZYME – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The company had revenue of $512.92 million during the quarter, compared to the consensus estimate of $227.40 million. During the same period in the previous year, the firm posted ($0.26) earnings per share. The company’s revenue was up 828.7% on a year-over-year basis. On average, research analysts expect that Zymeworks will post 1.31 EPS for the current fiscal year.

Insider Activity

In related news, EVP Adam Schayowitz sold 13,832 shares of Zymeworks stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $25.85, for a total value of $357,557.20. Following the sale, the executive vice president owned 23,205 shares of the company’s stock, valued at approximately $599,849.25. This trade represents a 37.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 37.73% of the company’s stock.

Institutional Trading of Zymeworks

A number of institutional investors have recently made changes to their positions in ZYME. Entropy Technologies LP bought a new position in Zymeworks in the third quarter valued at $220,000. Jump Financial LLC lifted its position in Zymeworks by 799.1% during the 3rd quarter. Jump Financial LLC now owns 230,236 shares of the company’s stock worth $6,099,000 after buying an additional 204,628 shares in the last quarter. HighVista Strategies LLC boosted its stake in shares of Zymeworks by 4.6% during the 3rd quarter. HighVista Strategies LLC now owns 35,578 shares of the company’s stock worth $942,000 after buying an additional 1,565 shares during the last quarter. Fisher Asset Management LLC boosted its position in Zymeworks by 759.9% during the third quarter. Fisher Asset Management LLC now owns 608,612 shares of the company’s stock valued at $16,122,000 after purchasing an additional 537,837 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its stake in shares of Zymeworks by 104.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 97,994 shares of the company’s stock worth $2,596,000 after purchasing an additional 50,127 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Key Headlines Impacting Zymeworks

These are some of the ZYME headlines that stood out recently:

  • Positive Sentiment: A report linked Zymeworks’ improved outlook to a milestone payment and a profitable quarter. The company’s latest reported results also beat the cited EPS consensus slightly, while revenue was well above estimates—supportive news, though milestone revenue may not recur. Milestone Payment Lifts Zymeworks Stock Outlook After Profitable Quarter
  • Positive Sentiment: Separate reports cited a higher TD Cowen price target, a bullish forecast from Truist, and Zymeworks reaching a new 52-week high after better-than-expected earnings. TD Cowen price target report Truist forecast report New 52-week high report
  • Negative Sentiment: HC Wainwright cut its estimates across several upcoming quarters, lowering its FY2026 EPS forecast to $1.19 from $1.51 and moving its FY2027 outlook from $1.32 profit to a projected $0.39 loss. The analyst retained a Buy rating and $56 target, but the revisions signal a less favorable earnings outlook beyond the recent quarter.

About Zymeworks

(Get Free Report)

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.

Featured Stories

Analyst Recommendations for Zymeworks (NASDAQ:ZYME)

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.